A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer

Author(s): Nur-Vaizura Mohamad, Ima-Nirwana Soelaiman, Kok-Yong Chin*

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 17 , Issue 4 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background and Objective: Prostate cancer is the most prevalent non-cutaneous cancer in men, which causes significant mortality among the patients. Since prostate cancer cells are stimulated by androgen, effective androgen ablation in men is one of the essential strategies in the management of prostate cancer.

Discussion: Several treatment options are available for different stages of prostate cancer. Hormone therapy known as androgen deprivation therapy (ADT) is the first line treatment used to treat advanced prostate cancer. Chemical castration by gonadotropin-releasing hormone agonists suppresses lutenizing hormone production, which in turn inhibits the production of testosterone and dihydrotestosterone. This will prevent the growth of prostate cancer cells. However, ADT causes deleterious effects on bone health because the androgens are essential in preserving optimal bone health in men.

Conclusion: Various observational studies showed that long-term ADT for advanced or metastatic prostate cancer was associated with decreased bone mineral density, as well as altered body composition that might affect bone health. Considering the potential impact of osteoporotic fracture, interventions to mitigate these skeletal adverse effects should be considered by physicians when initiating ADT on their patients.

Keywords: Prostate cancer, testosterone, androgen deprivation therapy, bone health, bone mineral density (BMD), radiotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [276 - 284]
Pages: 9
DOI: 10.2174/1871530317666170919112757
Price: $65

Article Metrics

PDF: 34